(SENS) Senseonics Holdings - Ratings and Ratios
CGM Systems, Glucose Monitoring, Implantable Sensors, Diabetes Management
SENS EPS (Earnings per Share)
SENS Revenue
Description: SENS Senseonics Holdings
Senseonics Holdings Inc (NYSE MKT:SENS) is a commercial-stage medical technology company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes. The companys flagship products, including Eversense, Eversense XL, Eversense E3, and Eversense365, are implantable CGM systems that enable real-time diabetes monitoring and management through a sensor, transmitter, and mobile app.
The companys products serve healthcare providers and patients through a network of distributors and strategic fulfillment partners, indicating a diversified revenue stream. With a presence in the US and international markets, Senseonics is well-positioned to capitalize on the growing demand for CGM systems. The global CGM market is expected to grow significantly, driven by increasing prevalence of diabetes and advancements in technology.
From a financial perspective, Senseonics has a market capitalization of approximately $407 million. The companys P/E forward multiple of 21.51 suggests that investors are pricing in future growth expectations. However, the absence of a trailing P/E ratio and a negative Return on Equity (RoE) of -745.67 indicate that the company is currently not profitable. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and operating expense management, which will be crucial in determining the companys path to profitability.
To further evaluate Senseonics prospects, its essential to monitor the companys product pipeline, regulatory developments, and competitive landscape. The CGM market is highly competitive, with established players like Dexcom and Medtronic. Senseonics ability to innovate and differentiate its products will be critical in maintaining market share and driving growth. Key metrics to track include the number of patients using Eversense, sensor accuracy, and user satisfaction.
SENS Stock Overview
| Market Cap in USD | 369m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2016-03-17 |
SENS Stock Ratings
| Growth Rating | -33.6% |
| Fundamental | 33.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -13.3% |
| Analyst Rating | 3.50 of 5 |
SENS Dividends
Currently no dividends paidSENS Growth Ratios
| Growth Correlation 3m | -76.9% |
| Growth Correlation 12m | 30.6% |
| Growth Correlation 5y | -61.4% |
| CAGR 5y | -31.03% |
| CAGR/Max DD 3y | -0.38 |
| CAGR/Mean DD 3y | -0.52 |
| Sharpe Ratio 12m | -0.77 |
| Alpha | 0.05 |
| Beta | 0.912 |
| Volatility | 51.34% |
| Current Volume | 4950.4k |
| Average Volume 20d | 4840.4k |
| Stop Loss | 0.4 (-11.1%) |
| Signal | 0.24 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-69.2m TTM) > 0 and > 6% of Revenue (6% = 1.63m TTM) |
| FCFTA -0.62 (>2.0%) and ΔFCFTA 0.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 194.0% (prev 290.8%; Δ -96.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.59 (>3.0%) and CFO -59.4m > Net Income -69.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (595.4m) change vs 12m ago -3.44% (target <= -2.0% for YES) |
| Gross Margin 19.75% (prev 12.04%; Δ 7.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 25.58% (prev 21.55%; Δ 4.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.75 (EBITDA TTM -59.2m / Interest Expense TTM 7.90m) >= 6 (WARN >= 3) |
Altman Z'' -43.75
| (A) 0.52 = (Total Current Assets 91.4m - Total Current Liabilities 38.8m) / Total Assets 100.4m |
| (B) -9.44 = Retained Earnings (Balance) -947.9m / Total Assets 100.4m |
| warn (B) unusual magnitude: -9.44 — check mapping/units |
| (C) -0.58 = EBIT TTM -61.3m / Avg Total Assets 106.0m |
| (D) -11.94 = Book Value of Equity -947.3m / Total Liabilities 79.3m |
| Total Rating: -43.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.17
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -17.92% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 2.64 = -0.23 |
| 5. Debt/Ebitda -0.94 = -2.50 |
| 6. ROIC - WACC (= -97.68)% = -12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 53.66% = 4.02 |
| 9. EPS Trend 37.50% = 1.88 |
What is the price of SENS shares?
Over the past week, the price has changed by +2.17%, over one month by -4.79%, over three months by -10.50% and over the past year by +2.78%.
Is Senseonics Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SENS is around 0.34 USD . This means that SENS is currently overvalued and has a potential downside of -24.44%.
Is SENS a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SENS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.4 | 217.8% |
| Analysts Target Price | 1.4 | 217.8% |
| ValueRay Target Price | 0.4 | -15.6% |
Last update: 2025-09-04 04:47
SENS Fundamental Data Overview
CCE Cash And Equivalents = 74.9m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 21.5054
P/S = 14.4919
P/B = 3.8962
Beta = 0.887
Revenue TTM = 27.1m USD
EBIT TTM = -61.3m USD
EBITDA TTM = -59.2m USD
Long Term Debt = 35.2m USD (from longTermDebt, last quarter)
Short Term Debt = 20.6m USD (from shortTermDebt, last quarter)
Debt = 55.8m USD (Calculated: Short Term 20.6m + Long Term 35.2m)
Net Debt = -13.9m USD (from netDebt column, last quarter)
Enterprise Value = 349.9m USD (369.1m + Debt 55.8m - CCE 74.9m)
Interest Coverage Ratio = -7.75 (Ebit TTM -61.3m / Interest Expense TTM 7.90m)
FCF Yield = -17.92% (FCF TTM -62.7m / Enterprise Value 349.9m)
FCF Margin = -231.3% (FCF TTM -62.7m / Revenue TTM 27.1m)
Net Margin = -255.2% (Net Income TTM -69.2m / Revenue TTM 27.1m)
Gross Margin = 19.75% ((Revenue TTM 27.1m - Cost of Revenue TTM 21.8m) / Revenue TTM)
Tobins Q-Ratio = -0.37 (set to none) (Enterprise Value 349.9m / Book Value Of Equity -947.3m)
Interest Expense / Debt = 3.89% (Interest Expense 2.17m / Debt 55.8m)
Taxrate = 21.0% (US default)
NOPAT = -61.3m (EBIT -61.3m, no tax applied on loss)
Current Ratio = 2.35 (Total Current Assets 91.4m / Total Current Liabilities 38.8m)
Debt / Equity = 2.64 (Debt 55.8m / last Quarter total Stockholder Equity 21.1m)
Debt / EBITDA = -0.94 (Net Debt -13.9m / EBITDA -59.2m)
Debt / FCF = -0.89 (Debt 55.8m / FCF TTM -62.7m)
Total Stockholder Equity = 5.64m (last 4 quarters mean)
RoA = -68.89% (Net Income -69.2m, Total Assets 100.4m )
RoE = -1227 % (set to none) (Net Income TTM -69.2m / Total Stockholder Equity 5.64m)
RoCE = -149.9% (set to none) (Ebit -61.3m / (Equity 5.64m + L.T.Debt 35.2m))
RoIC = -89.13% (NOPAT -61.3m / Invested Capital 68.8m)
WACC = 8.55% (E(369.1m)/V(424.8m) * Re(9.38%)) + (D(55.8m)/V(424.8m) * Rd(3.89%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 48.48 | Cagr: 2.12%
Discount Rate = 9.38% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -62.7m)
EPS Correlation: 37.50 | EPS CAGR: 274.2% | SUE: 0.0 | # QB: 0
Revenue Correlation: 53.66 | Revenue CAGR: 23.71% | SUE: 4.0 | # QB: 2
Additional Sources for SENS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle